The Italian Institute of Prophylaxis against Animal Diseases (IZS) to test effectiveness of BeesFree Inc.'s Technology in Combating Colony Collapse Disorder

WEST PALM BEACH, Fla., May 2, 2012 /PRNewswire/ -- BeesFree, Inc. (OTCBB: BEES), a company which owns patent pending technology that arrests the effects of CCD (Colony Collapse Disorder) on honeybees, announced that the Italian Experimental and Animal Prophylaxis Institute (IZS - Istituto Zooprofilattico Sperimentale) will be conducting an extensive laboratory and field project to test the effectiveness of BeesFree Inc.'s patent-pending technology.

RBCC Target Amarantus BioSciences Reports Positive Pre-Clinical Results of Parkinson’s Treatment

Rainbow BioSciences, LLC, the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), announced today that its current joint venture target, Amarantus BioSciences, Inc., has achieved positive results in a pre-clinical experiment demonstrating the potential of its new Parkinson’s disease therapy currently in development.

Avedro to Present Seven Scientific Research Posters at Leading Ophthalmic Meeting

Poster presentations at The Association for Research in Vision and Ophthalmology (ARVO)

Exactech Q1 Revenue Up 10% to $58.6 Million, Net Income $3.3 Million, Diluted EPS $0.25

Exactech, Inc. (Nasdaq:EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today revenue of $58.6 million for the first quarter of 2012, a 10% increase over $53.4 million in the first quarter of 2011. Net income was $3.3 million, or $0.25 per diluted share, compared to $3.0 million, or $0.22 per diluted share, in the same quarter a year ago.

Mintz Levin Attorney Mark J. Riedy to Speak at World Congress on Biotechnology & Bioprocessing

Mark J. Riedy, a Member of the Corporate & Securities Section and Energy & Clean Technology Practice at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., will give a plenary address at the World Congress on Biotechnology & Bioprocessing hosted by the Biotechnology Industrial Organization (BIO). The congress is being held April 29-May 2 in Orlando, Florida.

Parathyroid Surgeons Named Among Best Surgeons and Doctors in America Again in 2012

Tampa Surgeons Chosen Tops in Their Field by Patients and Doctors, Earning Each of the Major Physician Awards

Dyadic International Expands License Agreement With Abengoa

/PRNewswire/ -- Dyadic International, Inc. ("Dyadic")(OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, biochemical, biopharmaceutical and industrial enzyme industries, announced today that Abengoa Bioenergy New Technologies, Inc. ("Abengoa") has agreed to pay Dyadic $5.5 million for an expansion of its rights under the non-exclusive license agreement the parties entered into in February 2009.

Promedior Announces Presentation of Data at ARVO Demonstrating that Pentraxin-2 Suppresses Fibrosis, Neovascularization, and Vascular Leak in Retinal Disease Models

First in Class Pentraxin Therapeutic Represents a Promising New Mechanism for Treating Fibroproliferative Retinal Diseases

Simply Healthcare and New Century Health Sign Contract For Specialty Care Management

Collaborative program targets improved quality of cancer and heart disease care

Altor BioScience and the Melanoma Research Alliance to Co-Support Clinical Studies of Altor’s Novel IL-15 Superagonist for Metastatic Melanoma

Altor BioScience Corporation (Altor), a leading developer of immunotherapeutics for curative treatment of metastatic malignancies, announced today that it will jointly sponsor with the Melanoma Research Alliance (MRA) a clinical study of Altor’s novel IL-15 superagonist, ALT-803, against metastatic melanoma at the University of Washington. MRA is a public charity focused on funding the most promising melanoma research worldwide.

Rainbow Biosciences, LLC Enters into Letter of Intent with Amarantus BioSciences to Advance Parkinson’s Disease Program

Rainbow BioSciences, a subsidiary of Rainbow Coral Corp (OTCBB: RBCC) has executed a Letter Of Intent (“LOI”) to advance Amarantus BioSciences, Inc.’s (OTCBB: AMBS) Parkinson’s disease program, comprised of an early detection diagnostic blood test and a disease-modifying protein drug candidate.

GeneLink Anticipates Completion of Audit

Trading Symbol Change Expected To Be Temporary

Executives, Agency Officials Discuss National Bioeconomy Blueprint

Biotechnology Industry Organization: